The Top 10 World's Leading Diagnostics Companies
| Publication Date | January 2008 |
|---|---|
| Publisher | Venture Planning Grp. |
| Product Type | Report |
| Pages | 950 |
| ISBN Number | |
| Product Code | VEP00108 |
Buy this product or for assistance call +44 20 7060 7474
Summary
In a highly dynamic and fragmented in vitro diagnostics market, besieged by intense competition, rapid pace of technological innovations and the uncertainty regarding future government regulations, the ability to anticipate new competitive product introductions and marketing strategies is particularly important... and can spell the difference between success and failure. The TOP 10, a unique series of market intelligence studies first introduced by VENTURE PLANNING GROUP in 1987, is designed to provide the in vitro diagnostics industry executives, as well as companies planning to diversify into the diagnostics field, with strategically significant competitor information, analysis and insight, critical to the development and implementation of effective marketing and R&D programs. The study's major objectives include: to establish a comprehensive, factual, annually-updated and cost-effective information base on performance, capabilities, goals and strategies of the world's leading in vitro diagnostics companies; to help current suppliers realistically assess their financial, marketing and technological capabilities vis-a-vis leading competitors; to assist potential market entrants in evaluating prospective acquisitions and joint venture candidates; and to complement organizations' internal competitor information gathering efforts by providing strategic analysis, data interpretation and insight. The study provides an approximately 55-page worldwide strategic overview of the in vitro diagnostics market, including the 2006-2011 forecasts for major testing locations and laboratory disciplines. Moreover, five-year worldwide sales projections for the most dynamic market segments, such as molecular diagnostics, infectious diseases, tumor markers, and personal testing were developed. In addition, the study provides a concise review of major U.S. and international regulatory, economic, demographic, and social trends with potentially significant impact on the in vitro diagnostics market during the next five years. For each of the TOP 10 companies, the report provides: Executive Summary; Business Organization; Senior Management; Facilities and Employees; Technical Know-How; Product Portfolio Analysis; as well as Marketing Tactics; Financial Analysis; R&D Programs; Collaborative Arrangements; and Strategic Direction.
Content
- Executive Summary
- A 4-7 Page Synopsis of Key Sections.
- Business Organization
- History of The Diagnostics Business Evolution Important to Theunderstanding of The Company's Corporate Culture, Management Mentality and Strategies.
- Most Recent Significant Acquisitions, Divestitures and Organizationalchanges.
- Current Organizational Structure.
- Senior Management
- Profiles of Senior Managers.
- Facilities and Employees
- Major Administrative, Manufacturing and R&Dfacilities in The U S. and Abroad.
- Manufacturing Practices.
- New Plants under Construction.
- U S. and International Work Force Size and Distribution.
- Technological Know-How
- Internally Developed and Acquired in Vitro Diagnostic Technologies.
- Know-How in Biotechnology, Engineering, Electronics and Otherrelated Fields.
- Proprietary Technologies and Patent Litigations.
- Product Portfolio Analysis
- Review of Major Product Lines.
- Specifications, Features, Advantages, Weaknesses, Introduction Datesand Prices of Current Analyzers, Reagent Systems and Ancillary Products.
- Marketing Tactics
- The U S. and International Sales Force.
- Distribution Approaches for Centralized and Decentralized Testingmarkets.
- Healthcare System Programs.
- The 2006 Instrument Placements and Installed Base
- Instrument Placements and Total Installed Base in The U S. and International Markets, by Analyzer Type and Model.
- Sales and Profit Growth
- The 2002-2006 U S. and International Sales and Operating Profit Performance.
- The 2006 Reagent and Instrument Revenue by Product Line Andgeographic Region.
- R&D Expenditures and Major Programs
- Estimated 2006 Diagnostics R&D Budget.
- Research Facilities and Staff.
- New Technologies, and Products in Development, Including Their Specifications, Anticipated Prices and Introduction Dates.
- Collaborative Arrangements
- Major Joint Venture, Distribution, O E M. and Licensing Partners, Both Industrial and Academic.
- Terms of Collaborative Agreements and Specific Products Involved.
- Strategic Direction
- Specific Business, New Product Development and Marketing Strategies.
- Anticipated Acquisitions, Joint Ventures and Divestitures.
Delivery Details
PDF:Delivered by email usually within 12 to 24 UK business hours.
PRINT/CD-ROM:Despatched within 1 to 2 working days.
Related Products
Pharma & Healthcare
- Animal / Veterinary
- Biotechnology
- Cardiovascular
- Company Financials
- Company Reports (Pharmaceutical)
- Country Reports (Pharmaceutical)
- Deals & Alliances
- Dental
- Diagnostics
- Dietary
- Diseases
- Drug Delivery
- Drug Discovery
- Finance / Investment
- General Industry
- Generic Drugs
- Healthcare
- IT & eHealth
- Management / Strategy
- Medical Devices
- Medical Supplies
- OTC drugs
- Pharma Chemicals
- Pharmacy
- Prescription Drugs
- Production / Manufacturing
- Regulation & Policy
- Research (R&D)
- Sales & Marketing
- Technology
- Therapeutic
- Treatments
call +44 (0) 20 7060 7474
or email us
Resources
Why Report Buyer?
Advertising/Affiliates
View Our Publishers
News
About Us
Meet Us
Jobs
Contact Us
Categories and Subcategories











